Yupelri received FDA approval on November 2, 2018 [1]. It is indicated for the treatment of bronchopulmonary dysplasia (BPD) in premature infants.
What is Yupelri?
Yupelri is a nebulized bronchodilator containing the active ingredient revanna [1]. It is administered via inhalation using a nebulizer.
How does Yupelri work?
The exact mechanism of action of Yupelri in treating BPD is not fully understood. However, it is believed to relax airway smooth muscle, which may help to improve airflow in infants with BPD [1].
Who makes Yupelri?
Yupelri was developed by Kadmon Pharmaceuticals, which was acquired by Sanofi in 2022 [2].
When does Yupelri's patent expire?
Information regarding Yupelri's specific patent expiration dates is not readily available in the provided context. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may include details on Yupelri's intellectual property [3].
What are the side effects of Yupelri?
The most common side effects reported in clinical trials for Yupelri included apnea, sepsis, and feeding